{"schema_version":"secwatch.filing_event.v1","accession":"0001725160-23-000028","form_type":"8-K","ticker":"ZNTL","cik":"0001725160","company_name":"Zentalis Pharmaceuticals, Inc.","filed_at":"2023-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.323270+00:00","generated_at":"2026-06-19T16:17:34.887841+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Zentalis appoints Iris Roth as COO, effective Feb 13, 2023","bullets":["Iris Roth, Ph.D. appointed Chief Operating Officer effective February 13, 2023.","Dr. Roth previously led CD226 Axis immune checkpoint inhibitor development at GSK as VP Medicine Development Leader.","Initial base salary $434,476; target bonus 40% of base; severance for involuntary termination.","Granted stock options for 297,500 shares and RSUs for 52,500 shares, vesting four years.","Severance includes 9 months salary (12 months after change in control) and COBRA coverage."],"urls":{"canonical":"https://secwatch.observer/filing/0001725160-23-000028","json":"https://secwatch.observer/filing/0001725160-23-000028.json","markdown":"https://secwatch.observer/filing/0001725160-23-000028.md","text":"https://secwatch.observer/filing/0001725160-23-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725160/000172516023000028/0001725160-23-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725160/000172516023000028/zntl-20230213.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T16:17:34.887841+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c17c21fe90","claim":"Iris Roth was appointed as Chief Operating Officer at Zentalis Pharmaceuticals, Inc..","evidence_excerpt":"On February 13, 2023, Zentalis Pharmaceuticals, Inc. (the “Company”) publicly announced the appointment of Iris Roth, Ph.D. as Chief Operating Officer of the Company, effective as of February 13, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516023000028/0001725160-23-000028-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}